FDA Brief

Warning letters Drugs

FDA warning letter to

Zermat International S.A. de C.V.

High riskIssued Apr 6, 2023Posted Apr 18, 2023Center for Drug Evaluation and Research | CDER

FDA warns Zermat International about current good manufacturing practice violations for OTC drugs, including releasing out-of-specification lots without investigation.

What happened

FDA inspected Zermat International's drug manufacturing facility from October 10 to October 14, 2022. FDA found that the firm released and distributed OTC drug lots with out-of-specification viscosity and specific gravity results without investigation and also cited inadequate stability testing, process validation, quality unit oversight, and raw material testing. FDA reviewed the firm's November 2, 2022, response and found it inadequate.

What FDA found

  1. The firm did not thoroughly investigate out-of-specification results and released and distributed OTC drug lots with failing viscosity and specific gravity results without investigation.

    21 CFR 211.192
  2. The firm lacked an adequate written stability program and did not have stability data showing its OTC drugs met chemical and microbial specifications throughout their shelf life.

    21 CFR 211.166(a)
  3. The firm did not adequately validate its manufacturing processes and lacked ongoing process monitoring to show consistent drug quality.

    21 CFR 211.100(a)
  4. The quality control unit did not adequately oversee manufacturing, annual product review, complaint handling, or out-of-specification discrepancies before batch release.

    21 CFR 211.22
  5. The firm made OTC drugs with an active ingredient without testing incoming material for arsenic and a specified limit required by USP.

    United States Pharmacopeia (USP)
  6. The firm’s quality system did not adequately ensure the accuracy and integrity of data supporting the safety, effectiveness, and quality of its drugs.

What FDA wants

FDA tells Zermat to respond in writing within 15 working days and correct the violations promptly. The response must include detailed assessments and remediation plans for the laboratory/OOS, stability, process validation, quality unit, raw material testing, and data integrity issues, and FDA strongly recommends a qualified CGMP consultant.

Who should pay attention

  • U.S. distributors and retailers of Zermat OTC drug products
  • companies using Zermat as a contract manufacturer or supplier
  • quality teams auditing Mexican OTC drug manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk